Biogen
NEWS
It was a busy, busy week for clinical trial news and updates, largely driven by the annual ASCO meeting taking place June 3-7 in Chicago.
Biogen and Ionis Pharmaceuticals have announced results from the Phase III VALOR trial and an open-label extension (OLE) trial of tofersen.
A largely untested and unproven treatment for Alzheimer’s disease, called transcranial pulse stimulation (TPS), is becoming popular around the world, although experts are skeptical.
Sage Therapeutics and partner Biogen shared news that their phase III Skylark study has yielded promising results for women suffering from severe postpartum depression (PPD).
Most of Samsung’s investment will be in South Korea, and it expects to create 80,000 new jobs through 2026, or about 16,000 positions annually.
In honor of ALS Awareness Month, BioSpace spoke with leading researchers like Dr. Matthew Harms of Columbia University and Drs. Howard Berman and Stanley Appel at Coya Therapeutics.
Eisai and Biogen have completed the rolling submission of a Biologics License Application for lecanemab drug to the U.S. Food and Drug Administration.
In honor of World Lupus Day, BioSpace spoke with several companies making inroads in research and development for the treatment of the disease.
Biogen is bolstering its multiple sclerosis (MS) pipeline through a licensing agreement with Maine-based MedRhythms for its investigational digital therapeutic, MR-004.
JOBS
IN THE PRESS